Red
Brand Name(s):Leustat, Litak
Indication:Hairy cell leukaemia
Rationale:1,2,3
Considered:Oct-09
Review Date:Nov-22
Comments:
Drug Safety Update
Cladribine (Litak, Leustat) for leukaemia: reports of progressive multifocal encephalopathy (PML); stop treatment if PML suspected
Dec 2017